Team cracks 2 enzymes’ role in cancer mutation

(Credit: Getty Images)

Researchers have discovered the key role that the APOBEC3A and APOBEC3B enzymes play in driving cancer mutations by modifying the DNA in tumor genomes.

The work offers potential new targets for intervention strategies.

The study in the journal Nature Communications describes how the researchers identified the process by which APOBEC3A and APOBEC3B detect specific DNA structures, resulting in mutations at distinct positions within the tumor genome.

“It’s critical to understand how cancer cells accumulate mutations leading to hot spots that contribute to disease progression, drug resistance, and metastasis,” says corresponding author Rémi Buisson, University of California, Irvine assistant professor of biological chemistry.

“Both APOBEC3A and APOBEC3B were known to generate mutations in many kinds of tumors, but until now we did not know how to identify the specific type caused by each. This finding will allow us to develop novel therapies to suppress mutation formation by directly targeting each enzyme accordingly.”

In this study, graduate student Ambrocio Sanchez and postdoctoral fellow Pedro Ortega, both in Buisson’s laboratory at the UCI School of Medicine, developed a new method to characterize the particular kind of DNA modified by APOBEC3A and APOBEC3B.

It revealed that the two enzymes do not recognize the same DNA sequences and structures within the genomes of cancer cells.

Based on this observation, the researchers employed an innovative approach utilizing these unique target preferences to classify cancer patients who had accumulated mutations caused by each enzyme.

“The next steps are to investigate whether mutations caused by these enzymes lead to various types of therapy resistance,” Buisson says.

“It’s also critical to identify molecules that inhibit APOBEC3A and APOBEC3B to prevent mutations from forming. Our findings could, in the future, help to assess patient risk before treatment and suppress tumor evolution using the appropriate drug therapy.”

Other team members included undergraduate and graduate students and postdoctoral fellows from UCI, Harvard Medical School, the University of Southern California, the University of Texas at San Antonio, and the University of Minnesota.

Support for the work came from the National Institutes of Health’s Research Supplements to Promote Diversity in Health-Related Research program; California Institute for Regenerative Medicine; the European Molecular Biology Organization; the Cancer Prevention and Research Institute of Texas; the National Cancer Institute; the National Institute of Allergy and Infectious Diseases; and access to UCI’s Genomics Research and Technology Hub, affiliated with the Chao Family Comprehensive Cancer Center.

Source: UC Irvine